Inflammation, mitochondrial impairment, oxidative stress, and insulin resistance may all contribute to disease progression
Previously, we have been mostly prescribing it for our patients who either need significant weight loss before surgery or those who are post-surgery and struggling, either not having lost enough or gaining back weight
Also, anyone with severe gastrointestinal (digestive) issues, such as gastroparesis (a condition where the stomach doesnt empty properly), should be cautious, as semaglutide can worsen these conditions
The right option depends on: Why tirzepatide is not an option: cost, insurance denial, medical history, or needle aversion, each point toward different alternatives Weight loss goal: patients needing 15%+ loss are best served by GLP-1 medications
Although there is evidence that DPP-4 inhibitors confer cardiovascular safety and renoprotection, the potential risks of hospitalization for heart failure and acute pancreatitis are disadvantages to their use as add-on therapy